Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25630738 | 1.00 | PDK1 (0.59) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL25046838 | 0.92 | PDK1 (0.50) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL16939085 | 0.92 | PDK1 (0.50) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL14971339 | 0.87 | USP2 (0.50) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL59641 | 0.85 | USP2 (0.54) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL13765388 | 0.85 | USP2 (0.54) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL194709 | 0.85 | USP2 (0.54) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL194710 | 0.85 | USP2 (0.54) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL15655665 | 0.85 | USP2 (0.54) | PDK1USP2SMN1; SMN2RECQLMAPT | |
| SCHEMBL3498202 | 0.85 | USP2 (0.48) | PDK1USP2SMN1; SMN2RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4633734-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | Wavebreak Therapeutics, LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024129881-A1 | COMPOUNDS, COMPOSITIONS, AND MEZHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN MISFOLDING | WAVEBREAK THERAPEUTICS LIMITED (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-4313989-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-7186718-B2 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| EP-1421082-B1 | PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | US | disclosed |
| EP-1421070-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421082-A1 | NEW PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003018576-A1 | NEW PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018566-A1 | NEW PIPERIDINYL DERIVATES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | PDK1 1435/4885USP2 73/4885SMN1; SMN2 3676/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | PDK1 1451/4885USP2 4722/4885SMN1; SMN2 3731/4885 |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | CCR5, CCR2, CXCR2 | PDK1 2228/4885USP2 4655/4885SMN1; SMN2 3862/4885 |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, HIPK3 | PDK1 259/4885USP2 1613/4885SMN1; SMN2 3266/4885 |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, PGK1 | PDK1 201/4885USP2 2243/4885SMN1; SMN2 3520/4885 |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | PDK1 1435/4885USP2 73/4885SMN1; SMN2 3676/4885 |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | PDXK, HIPK1, HIPK3 | PDK1 259/4885USP2 1613/4885SMN1; SMN2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.